RxDoctor Payments Data

Shondra Smith, MD

Dermatology · Lake Charles, LANPI 1134117898

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,052 of the $1,207 with a category attached, or 87.2%. 14 manufacturers reported payments, led by AbbVie at 33.6% of the total. That places this record below the midpoint for dermatology clinicians in LA, where the typical reported total is $5,293.

$1,207in general payments, 2019–2025

Across 59 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$406
  • Novartis$156
  • Johnson & Johnson$155
  • Phathom Pharmaceuticals, Inc.$125
  • Merz North America, Inc.$93
  • Sanofi$52
  • plus $220 from 8 others
$326,612in research payments, 2019–2025

Across 63 payments — averaging $5184.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$139K
  • Janssen Research & Development, LLC$88K
  • Eli Lilly$26K
  • Pfizer$23K
  • Novartis$20K
  • Takeda Pharmaceuticals U.S.A., Inc.$17K
  • plus $13K from 3 others

What the payments were for

  • Food & beverage$1,05287%
  • Education$15513%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,207 in reported general payments places this provider in the 20th percentile of 189 dermatology providers in Louisiana.

See all dermatology providers in Louisiana

Medicare billing

Part B allowed, 2024
$78,932
Medicare patients
310
Services billed
1,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ketoconazole59$1,832
Fluorouracil32$1,706
Metronidazole18$966
Clindamycin Phosphate18$544
Triamcinolone Acetonide43$362
Clobetasol Propionate12$314
Mupirocin11$63

Paid to pharmacies, not to this prescriber.

Other dermatology in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →